Article

ASCRS 2020: Eyevance portfolio brimming with product launches

Author(s):

Alex Delaney-Gesing
Conferences|ASCRS

Ophthalmology Times' Sheryl Stevenson speaks with Julie Speed, chief commercial officer of Eyevance Pharmaceuticals, on what's on the agenda for the company's porfolio this year with product launches during the 2020 ASCRS virtual meeting.
 

 

See more ASCRS coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
Ophthalmologists present data on perfluorohexyloctane eye drops
August 22nd 2025

Ophthalmologists present data on perfluorohexyloctane eye drops

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
August 22nd 2025

Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment

Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery
August 22nd 2025

Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery

EyePod
August 22nd 2025

ASCRS 2020: Assessing aberration of monofocal toric IOL with enhanced optic recovery, alignment

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience
August 22nd 2025

Ravi Patel, MD, shares ASCRS 2025 insights on enVista ASPIRE IOL user experience

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops
August 22nd 2025

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops

© 2025 MJH Life Sciences

All rights reserved.